What Happened
- Prime Minister Narendra Modi launched the nationwide Human Papillomavirus (HPV) Vaccination Programme from Ajmer, Rajasthan on February 28, 2026.
- The programme targets all 14-year-old girls across India, providing a single-dose HPV vaccine free of cost at government health facilities.
- The initiative aims to cover approximately 1.15 crore girls annually across all States and Union Territories.
- The vaccination is voluntary and will be administered through the existing Universal Immunization Programme (UIP) infrastructure.
- India Medical Association (IMA) welcomed the programme, noting that a woman dies of cervical cancer every 8 minutes in India.
Static Topic Bridges
Human Papillomavirus (HPV) and Cervical Cancer
Human Papillomavirus is a group of over 200 related viruses, of which high-risk types — primarily HPV 16 and HPV 18 — are responsible for approximately 70% of cervical cancer cases in India. HPV is transmitted through sexual contact, and persistent infection with high-risk types drives carcinogenesis by producing viral oncoproteins E6 and E7, which disrupt host tumour suppressor proteins p53 and retinoblastoma protein (pRb). Cervical cancer begins as a precancerous lesion (cervical intraepithelial neoplasia, CIN) that progresses over years to invasive cancer.
- India records nearly 80,000 new cervical cancer cases annually and over 42,000 deaths — one death every 8 minutes.
- India accounts for approximately one-fifth of the global cervical cancer burden.
- HPV 16 alone accounts for 57.5% of cervical cancers in India; HPV 18 accounts for a further 10.4%.
- The vaccine used in India's programme is Gardasil-4 (quadrivalent), which targets HPV types 6, 11, 16, and 18.
- WHO efficacy data: HPV vaccines demonstrate 93–100% efficacy in preventing cervical cancer from vaccine-covered HPV types.
Connection to this news: The nationwide rollout is a primary prevention strategy using prophylactic vaccination before girls become sexually active, directly targeting the two HPV types responsible for the majority of cervical cancers in India.
Single-Dose HPV Vaccine Schedule
In April 2022, the WHO Strategic Advisory Group of Experts (SAGE) on Immunization revised the HPV vaccination schedule, finding that a single dose provides protection comparable to two-dose regimens for females aged 9 to 20 years. This was a landmark shift from the earlier two-dose and three-dose schedules, making the vaccine logistically and financially viable for large-scale national programmes in lower-middle income countries.
- Original schedule: 3 doses; later revised to 2 doses for girls under 15; now 1 dose sufficient per WHO SAGE 2022 recommendation.
- Single-dose protection is attributed to strong immune memory responses, with antibody levels remaining substantially higher than those seen in natural infection.
- India has adopted the single-dose schedule backed by the 2022 WHO SAGE findings.
- For immunocompromised individuals and women older than 20, a two-dose schedule remains recommended.
Connection to this news: India's adoption of the single-dose schedule makes the programme operationally feasible at a national scale — covering 1.15 crore girls per year without the dropout risk associated with multi-dose schedules.
Universal Immunization Programme (UIP) and National Health Mission
The Universal Immunization Programme (UIP), launched in 1985 and expanded under the National Health Mission (NHM) since 2005, is one of the world's largest public health programmes. It currently provides free vaccination against 12 vaccine-preventable diseases to all children from birth to 16 years, and to pregnant women.
- UIP covers 12 diseases nationally and sub-nationally: Tuberculosis, Diphtheria, Pertussis, Tetanus, Polio, Measles, Rubella, Hepatitis B, Haemophilus Influenzae type B (Hib), Rotavirus diarrhoea, Pneumococcal Pneumonia, and Japanese Encephalitis.
- UIP funding is entirely borne by the Central Government (budget: ₹7,234 crore in 2022).
- HPV vaccination is being added as a dedicated special programme under the UIP framework.
- Digital tracking of vaccinations is managed through the U-WIN (Universal WIN) portal.
Connection to this news: The HPV programme leverages the existing UIP delivery infrastructure — ASHA workers, ANMs, government health facilities — to achieve the 1.15 crore annual coverage target, making it an extension of India's established preventive healthcare architecture.
Women's Health as a Public Policy Priority
The addition of HPV vaccination to India's public health portfolio reflects the Sustainable Development Goal (SDG) 3 commitment to ensure healthy lives and promote well-being, particularly SDG 3.1 (maternal health) and SDG 3.4 (non-communicable diseases). The WHO's global strategy to eliminate cervical cancer calls for 90% of girls to be fully vaccinated with the HPV vaccine by age 15 by 2030.
- WHO's 90-70-90 elimination strategy: 90% vaccination coverage; 70% screening coverage; 90% treatment coverage for detected lesions.
- India's National Programme for Prevention and Control of Cancer (NPCC) has provided cervical cancer screening through VIA (Visual Inspection with Acetic Acid) at district hospitals.
- Cervical cancer is the second most common cancer among women in India (after breast cancer).
- The economic cost of cervical cancer treatment places a disproportionate burden on poor and rural households.
Connection to this news: The nationwide HPV vaccination programme represents a shift from curative to preventive strategy for cervical cancer, aligning India with the WHO elimination target and addressing the equity dimension — reaching girls in rural and peri-urban areas through the government health system.
Key Facts & Data
- Target age group: 14-year-old girls (nationwide)
- Annual coverage target: 1.15 crore girls
- Vaccine: Gardasil-4 (quadrivalent HPV vaccine — types 6, 11, 16, 18)
- Dose schedule: Single dose (per WHO SAGE 2022 recommendation)
- Cost to beneficiary: Free (government-funded)
- Launch location: Ajmer, Rajasthan (February 28, 2026)
- India's annual cervical cancer deaths: ~42,000 (one death every 8 minutes)
- India's annual new cervical cancer cases: ~80,000
- India's share of global cervical cancer burden: ~1/5th
- Vaccine efficacy against cancer from covered HPV types: 93–100%
- HPV 16 and 18 together account for ~70% of cervical cancers in India